All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Visual abstract | Ruxolitinib versus basiliximab in adult patients with steroid-refractory aGvHD
Bookmark this article
Acute graft-versus-host disease (aGvHD) occurs in approximately 30–50% of patients who receive allogeneic hematopoietic stem cell transplantation (allo-HSCT).1
Although glucocorticoids are the standard first-line treatment, they fail to yield a response in almost 60% of patients; outlining the need for second-line treatment options.1 The current recommended second-line treatment for steroid-refractory aGvHD is ruxolitinib, a JAK inhibitor, with basiliximab also considered a feasible salvage therapy option.1
- Lui J, Fan Z, Xu Z et al. Ruxolitinib versus basiliximab for steroid-refractory acute graft-versus-host disease: a retrospective study. Ann Hematol. 2023;102(10):2865-2877. DOI: 1007/s00277-023-05361-9Lui J, Fan Z, Xu Z et al. Ruxolitinib versus basiliximab for steroid-refractory acute graft-versus-host disease: a retrospective study. Ann Hematol. 2023;102(10):2865-2877. DOI: 1007/s00277-023-05361-9
Your opinion matters
8 votes - 27 days left ...
Newsletter
Subscribe to get the best content related to GvHD delivered to your inbox